Paulness
3時間前
NEWS -- Scorpius Holdings Announces Removal of NYSE American Trading Suspension; Expected to Resume Normal Trading on August 2, 2024
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American. The NYSE Regulation staff determined that the Company's common stock was now trading above the threshold of low selling price issues as further defined by Section 1003(f)(v) of the NYSE American Company Guide. Scorpius’ common stock is expected to resume trading on the NYSE American on Friday, August 2, 2024, under the symbol "SCPX" and Cusip “42237K 508.”
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit https://www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the Common Stock resuming trading on the NYSE American on Friday, August 2, 2024, under the symbol "SCPX." Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to resume trading on Friday, August 2, 2024 and have its Common Stock remain listed and recommence trading on the NYSE American; the Company’s financing needs; its cash balance being sufficient to sustain operations and its ability to raise capital when needed; the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements; regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO; and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://ir@scorpiusbiologics.com
Paulness
6日前
NEWS -- Scorpius Holdings Set to Launch First Mammalian cGMP Campaign at San Antonio Facility in the 2024 3rd Quarter
DURHAM, N.C., July 24, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced that the Company expects to launch its first cGMP mammalian manufacturing campaign at its San Antonio manufacturing facility in the 3rd quarter of 2024. This milestone highlights the expansion of the Company’s biomanufacturing capabilities, particularly in the field of mammalian cell culture production for advanced biopharmaceuticals.
Scorpius has previously initiated cGMP activities in its microbial facilities, and the commencement of mammalian cGMP campaigns marks a significant development as it opens additional revenue streams for the Company’s CDMO operations. Scorpius boasts a dedicated mammalian cell culture facility with cGMP-compliant controlled cleanrooms illustrating Scorpius' commitment to providing tailored and adaptable manufacturing solutions.
Jeff Wolf, CEO of Scorpius, remarked, “I am extremely proud of what our team has accomplished in a short period of time. Our manufacturing and quality teams have worked exceptionally hard to get our mammalian facilities operational in less than two years, well ahead of the typical timing for such complex buildouts. Scorpius is now extremely well-positioned to support a wide range of early-stage clinical programs."
“Our focus at Scorpius is providing each client the personalized attention and systematic flexibility they deserve. Our facility's design includes cleanrooms with mobile equipment, allowing for easily customized configurations to meet the specific needs of each project. Our strategy is to expand our scope of services as our clients advance their respective programs through clinical development. Looking ahead, Scorpius has already secured bookings for additional cGMP activities in the mammalian building for 2025, demonstrating the demand and confidence in our expanded capabilities,” concluded Mr. Wolf.
Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit https://www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as launching Scorpius’ first cGMP mammalian manufacturing campaign at its San Antonio manufacturing facility in the 3rd quarter of 2024, opening additional revenue streams for Scorpius’ operations, being extremely well-positioned to support a wide range of early-stage clinical programs, expanding the scope of services as Scorpius’ clients advance their respective programs through clinical development. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to launch its first cGMP mammalian manufacturing campaign and open additional revenue streams as planned; expand its large molecule biomanufacturing CDMO services and continue to grow revenue; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://ir@scorpiusbiologics.com
Paulness
2週前
NEWS -- Scorpius Holdings Successfully Executes First cGMP Microbial Batches at San Antonio Facility
Company poised to execute additional cGMP activities throughout the remainder of the year
DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius’ support for manufacturing programs through clinical manufacturing, with aspirations for future commercial activities.
Scorpius' facilities have already attracted significant interest, resulting in a substantial backlog of client program bookings. This achievement underscores Scorpius' ability to meet the stringent regulatory and client-driven standards essential for the contract manufacturing of microbial biologics. It also highlights the trust and confidence that clients place in its services. Scorpius is poised to execute additional cGMP activities throughout the remainder of the year, reinforcing its commitment to advancing U.S.-based GMP manufacturing capabilities.
Jeff Wolf, CEO of Scorpius Holdings, remarked, "We are thrilled to have successfully completed our first cGMP microbial batches at the San Antonio facility. This milestone is a result of the dedication and collaboration among Scorpius’ manufacturing, process development, quality, and operations teams. The successful execution is a testament to the robust systems we have built and marks another step forward in our commitment to U.S. based cGMP activities for both current and future Scorpius clients."
"The Company remains dedicated to leveraging our advanced capabilities to support our clients' needs and contribute to the advancement of breakthrough therapies. With completion of this milestone, we believe that Scorpius is ready to further solidify its position as a leader in clinical scale microbial manufacturing, offering our clients unparalleled quality and service," concluded Wolf.
Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit https://www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as Scorpius being poised to execute additional cGMP activities throughout the remainder of the year; aspirations for future commercial activities; Scorpius being ready to further solidify its position as a leader in clinical scale microbial manufacturing, offering its clients unparalleled quality and service Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to validate its microbial facilities; expand its large molecule biomanufacturing CDMO services and continue to grow revenue; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://ir@scorpiusbiologics.com
Paulness
2週前
NEWS -- Scorpius Holdings Announces Reverse Stock Split
DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company’s Board of Directors approved a 1-for-200 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”), to increase the selling price of the Company’s Common Stock in order to regain compliance with the requirements and policies of the NYSE American. However, there can be no assurance that that the Reverse Stock Split will increase the Company’s stock price sufficiently in order to meet any requirements and policies of the NYSE American.
The Reverse Stock Split will take legal effect at 11:01 P.M. Eastern Time on July 17, 2024, and the Company's Common Stock will open for trading on the OTC Markets on July 18, 2024, on a post-split basis, under the existing ticker symbol "SCPX" but with new CUSIP number 42237K508.
At Scorpius Holdings, Inc’s Annual Meeting of Shareholders (the “Annual Meeting”) held on July 15, 2024, the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to effect a reverse stock split of its Common Stock at a ratio of between 1-for-5 to 1-for-200, with the ratio within such range to be determined at the discretion of the Company’s Board. Following the Annual Meeting, the Board approved a final split ratio of 1-for-200. Following the Reverse Stock Split, the ownership percentage of each stockholder will remain unchanged, other than with respect to fractional shares.
Additional details regarding the Company’s Reverse Stock Split can be found in the Current Report on Form 8-K that the Company will file with the SEC.
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit https://www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding regaining compliance with the requirements and policies of the NYSE American. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to successfully appeal the determination to the Exchange’s Listing Qualifications Panel and have its Common Stock remain listed and recommence trading on the NYSE American; the Company’s financing needs; its cash balance being sufficient to sustain operations and its ability to raise capital when needed; the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements; regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO; and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://ir@scorpiusbiologics.com
Paulness
1月前
NEWS -- Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal
DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today reported that it received notice from the NYSE American of its determination to commence delisting proceedings of the Company’s common stock from the exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low-selling price of the Company’s common stock. The Company plans to appeal the determination to the Exchange’s Listing Qualifications Panel, although there can be no assurance of a successful outcome.
Scorpius CEO Jeff Wolf commented, “Despite recent positive developments, the NYSE American has made the unfortunate decision to suspend trading in our securities based on our per-share price. We strongly disagree with the ruling and plan to appeal. We look forward to providing further updates.”
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit https://www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as the Company’s plans to appeal the determination to the Exchange’s Listing Qualifications Panel and the outcome of the appeal from current expectations include, among others, the ability of the Company to successfully appeal the determination to the Exchange’s Listing Qualifications Panel and have its common stock remain listed on the NYSE American; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure-play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://ir@scorpiusbiologics.com
Paulness
2月前
NEWS -- Scorpius Holdings and Beyond Imagination Announce Trailblazing Partnership to Utilize Autonomous AI-Powered Humanoid Robots for American Biomanufacturing
Collaboration aims to enhance biomanufacturing reliability, scalability and efficiency
Autonomous humanoids designed to complement human labor and
enhance productivity through 24/7 operational capabilities
Beyond’s Hive Mind capability allows autonomous humanoids to share and scale biomanufacturing knowledge and improve collective intelligence and operational efficiency
DURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced a groundbreaking strategic partnership with Beyond Imagination, Inc. (“Beyond”), a US-based developer of autonomous AI-powered humanoid robots. The goal of the collaboration is to introduce advanced AI robotics to enhance biomanufacturing productivity and efficiency, as well as bolster US preparedness for pandemics and other crises.
Beyond Imagination’s autonomous humanoids in action
The partnership aims to address the significant challenges posed by the increased demand for rapid-scale biomanufacturing and the limited supply of skilled labor. At the heart of this effort is the introduction of Beyond’s autonomous humanoids that possess the ability to learn from and collaborate with human colleagues, continuously improving their capabilities. AI robotics have been deployed in other industries, where they excel at learning new procedures and protocols and deploy these learnings to exacting standards. Beyond’s AI robotics platform has the potential to seamlessly integrate into existing workflows in the biomanufacturing regulated environment, thereby enhancing both efficiency and output.
One of the most significant benefits of Beyond’s autonomous humanoids is their ability to operate nearly 24/7, with the potential to enhance manufacturing facility utilization and productivity. Beyond’s proprietary AI technology also features Hive Mind capability, which allows their autonomous humanoids to share knowledge and improve collective intelligence to increase operational efficiency.
Beyond’s video demonstration of its autonomous humanoids in action is available at: https://youtu.be/nhgtrSITeqU?si=lZedcsgspNG2eWke
Dr. Harry Kloor, Ph.D., Ph.D., Executive Co-founder and CEO of Beyond Imagination, stated, “This partnership marks a major advance in the integration of advanced AI robotics into vital sectors, setting the foundation for a future where technology and human expertise align to transform the biomanufacturing and pharmaceutical industries. We are excited to work closely with the Scorpius team to improve biomanufacturing production for the benefit of customers and ultimately patients. Together, we look forward to ushering in a new age of technological innovation in biomanufacturing, pharmaceutical manufacturing, and beyond.” Dr. Kloor continued, “Beyond’s synthetic AI Brain is modeled after the multi-lobe structure of the human brain, enabling it to learn many skilled jobs and operate safely alongside humans.”
Ray Kurzweil, Ph.D., Google’s Chief Futurist, best-selling author, and one of the world's leading inventors, thinkers, and futurists, is an investor in Beyond Imagination and contributed significant patents. Dr. Kurzweil further noted: “In much the same way that Tesla disrupted the car industry, humanoid robots are poised to disrupt nearly every sector, including the pharmaceutical and biomanufacturing industries. In fact, Elon Musk himself believes that humanoid robots will become more valuable than cars. I couldn’t agree more, and believe this partnership with Scorpius positions the two companies to transform the biomanufacturing industry by accelerating the production of lifesaving therapies.”
Jeff Wolf, CEO of Scorpius, commented, "We are thrilled about our partnership with Beyond Imagination, which represents a pivotal step in leveraging AI and robotics to support American biomanufacturing. Beyond’s humanoids incorporate cutting edge AI technology, and we have partnered with Beyond to develop capabilities that include performing complex lab tasks and enhancing the precision and quality that our manufacturing processes demand.
Mr. Wolf continued, “We have seen growth in customer demand, and as our clients evolve to commercial production, we believe these autonomous humanoids will enable us to scale production at unprecedented rates. Recent global events have also highlighted the critical need for biomanufacturing readiness, including pandemics and national threats where traditional approaches requiring extensive at-the-ready manpower may inhibit the rapid production of life-saving drugs. We believe that the innovative use of autonomous humanoids can help ensure that production can pivot swiftly to support national emergencies. We look forward to working with Beyond to leverage their autonomous humanoids into the future of biomanufacturing.”
Beyond Imagination, Inc.
Beyond Imagination is a trailblazer in the development of AI-based autonomous humanoid robots. The Beomni AI Brain enables the training and deployment of “Expert Minds” for specific professions. This highly scalable technology is being targeted for deployment in many fields, including the biomanufacturing and pharmaceutical fields. Beyond Imagination’s stellar team of visionaries has been actively piloting and refining its humanoid in real-world environments for more than three years, demonstrating advanced real-world capabilities.
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit https://www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as the collaboration enhancing biomanufacturing reliability, scalability and efficiency; autonomous humanoids complementing human labor and enhancing productivity; the collaboration bolstering US preparedness for pandemics and other crises; the partnership addressing the significant challenges posed by the increased demand for rapid-scale biomanufacturing and the limited supply of skilled labor; the potential of the humanoids to seamlessly integrate into existing workflows in the bio manufacturing regulated environment, thereby enhancing both efficiency and output; the partnership marking a major advancement in the integration of advanced AI robotics into vital sectors, setting the foundation for a future where technology and human expertise align to transform the biomanufacturing and pharmaceutical industries; humanoid robots being poised to disrupt nearly every sector; humanoid robots becoming more valuable than cars; the partnership between Beyond Imagination and Scorpius positioning their two companies to transform the biomanufacturing industry by accelerating production of lifesaving therapies; the autonomous humanoids enabling Scorpius to scale production at unprecedented rates; and the innovative use of autonomous humanoids helping ensure that production can pivot swiftly to support national emergencies. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the partnership to derive the benefits anticipated, the ability of the humanoid robots to perform as expected including enhanced biomanufacturing reliability, scalability and efficiency and scale products at unprecedented rates and ensure that production can pivot swiftly, the adoption and acceptance of humanoid robots in the pharmaceutical and biomanufacturing industries, the Company’s ability attract new customers, profit from its bookings and continue to grow revenue; the ability to capture a meaningful market share; the ability to generate meaningful cash flow and become cash flow positive; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://ir@scorpiusbiologics.com
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Renee
2週前
Golden Cross
4週前
TommyBoyTrader9460
1月前
zino
1月前
dshade
2月前
Invest-in-America
2月前
OldJames
2月前
glenn1919
2月前
